Centessa Pharmaceuticals (CNTA) said late Thursday it priced an underwritten public offering of about 15.3 million American depositary shares at $14.75 per ADS for expected gross proceeds of about $225 million.
Each ADS represents one ordinary share. The offering was upsized from $150 million.
Underwriters have been granted a 30-day option to buy up to about 2.3 million additional ADSs.
The offering is set to close around Sept. 16.